Astrazeneca Pharma India Ltd vs Iol Chemicals Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8299 as of 04 May 09:01 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of IOL Chemicals & Pharmaceuticals Ltd changed from 12.4 on March 2022 to 17.8 on March 2025 . This represents a CAGR of 9.46% over 4 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 2077 crore on March 2022 to ₹ 1796 crore on March 2025 . This represents a CAGR of -3.56% over 4 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 585.68 crore as compare to the Sep '25 revenue of ₹ 574.41 crore. This represent the growth of 1.96% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 51.36 crore as compare to the Sep '25 ebitda of ₹ 63.96 crore. This represent the decline of -19.7% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 29.97 crore to ₹ 20.58 crore over 7 quarters. This represents a CAGR of -19.33% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of IOL Chemicals & Pharmaceuticals Ltd changed from 7.92 % on March 2021 to 23.25 % on March 2025 . This represents a CAGR of 24.03% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors.
Its extensive expertise in both API and specialty chemicals strengthens the business model and opens doors to diversified growth opportunities. Within the API segment, IOL develops and supplies a wide range of essential products utilized by pharmaceutical companies worldwide for the production of key medicines.
It serves as a global supplier of various APIs, including Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, and Fenofibrate, alongside other APIs, and maintains a significant presence in all major therapeutic categories. In the Specialty Chemicals division, IOL manufactures Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid (MCA), and Acetyl Chloride.

FAQs for the comparison of Astrazeneca Pharma India Ltd and IOL Chemicals & Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or IOL Chemicals & Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of IOL Chemicals & Pharmaceuticals Ltd is 2,765 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and IOL Chemicals & Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and IOL Chemicals & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and IOL Chemicals & Pharmaceuticals Ltd?

As of May 4, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, IOL Chemicals & Pharmaceuticals Ltd stock price is INR ₹94.2.

How do dividend payouts of Astrazeneca Pharma India Ltd and IOL Chemicals & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and IOL Chemicals & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.